Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nofazinlimab + Lenvatinib in 1L Advanced Hepatocellular Carcinoma
NCT04194775Phase 3Active, not recruiting
- Sponsor
- CStone Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Nofazinlimab (CS1003) + Lenvatinib with Placebo + Lenvatinib (2 arms). Primary endpoint: Overall Survival. Started Dec 2019; status: active, not recruiting.
02
Drugs
nofazinlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04194775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04194775.